FDA Expands Nogapendekin Alfa Inbakicept-pmln Plus BCG Indication for Bladder Cancer

Overview

On October 14, 2026, the FDA expanded the indication for intravesical nogapendekin alfa inbakicept-pmln plus BCG to adults with BCG-unresponsive, high-grade papillary-only NMIBC. The expansion relied on efficacy established in patients with CIS and the FDA’s assessment of clinical and nonclinical similarities, rather than a separate efficacy trial in papillary-only disease. The original trial reported a 62% complete response rate in patients with CIS, with or without papillary tumors.

Background

The original FDA indication for nogapendekin alfa inbakicept-pmln plus BCG covered BCG-unresponsive NMIBC with CIS, with or without papillary tumors; the October 2026 action added high-grade papillary-only disease. The FDA cited overlapping characteristics of CIS and high-grade papillary tumors: they frequently coexist and can be difficult to distinguish pathologically, although their growth patterns differ. The prescribing information warns that delaying cystectomy may result in metastatic bladder cancer, which the FDA noted can be lethal.

Data Highlights

Key Findings

• The October 14, 2026, FDA action added adults with BCG-unresponsive, high-grade papillary-only NMIBC to the indication for nogapendekin alfa inbakicept-pmln plus BCG.
• The expansion was based on previously established efficacy in patients with CIS and the FDA’s assessment of clinical and nonclinical similarities; the article reports no separate efficacy trial in papillary-only disease supporting the expansion.
• In Cohort A of QUILT-3.032, the complete response rate was 62%; among responders, 58% maintained response for at least 12 months and 40% for at least 24 months.
• The recommended regimen is 400 mcg intravesically with BCG weekly for 6 weeks. A second induction course may be given at month 3 for residual CIS and/or high-grade Ta tumors; maintenance consists of 3 weekly instillations at months 4, 7, 10, 13, and 19, with additional 3-week courses possible through month 37.
• The FDA advised discontinuation for persistent disease after a second induction course, recurrence, progression, or unacceptable toxicity. The prescribing information warns that delaying cystectomy may result in metastatic bladder cancer.
• The FDA is finalizing guidance on using efficacy evidence from patients with CIS to support treatments for BCG-unresponsive, high-grade papillary-only NMIBC.

Clinical Implications

The expanded indication includes adults with BCG-unresponsive, high-grade papillary-only NMIBC. The FDA advised discontinuing treatment for persistent disease after a second induction course, recurrence, progression, or unacceptable toxicity. The prescribing information warns that delaying cystectomy may result in metastatic bladder cancer.

Conclusion

The FDA extended the nogapendekin alfa inbakicept-pmln plus BCG indication to high-grade papillary-only BCG-unresponsive NMIBC by extrapolating evidence from the CIS population. The source reports the original trial’s response outcomes and emphasizes treatment-related adverse reactions and the cystectomy warning.

Related Resources & Content

1. US Food and Drug Administration, FDA, 2026 -- FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
2. US Food and Drug Administration, FDA, 2024 -- FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
3. MDSpire News, MDSpire News, n.d. -- FDA Expands Bladder Cancer Regimen
4. The ASCO Post, The ASCO Post, 2020 -- Novel Indications and New Drugs for the Treatment of Bladder Cancer
5. The ASCO Post — FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Some Advanced Bladder Cancers
6. The ASCO Post — FDA Approves Atezolizumab for Advanced Urothelial Carcinoma
7. FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
8. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
9. FDA Expands Bladder Cancer Regimen
10. Novel Indications and New Drugs for the Treatment of Bladder Cancer
11. FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer | FDA
12. BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drug and Biological Prodcuts for Treatment
13. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
14. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf
15. Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG in BCG-Unresponsive NMIBC with Carcinoma In Situ ± Papillary Disease | Journal of Urology
16. Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte–Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer - PMC
17. label
18. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial - PubMed
19. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment | Journal of Urology